Journal rankings · indicator year 2004
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2004
Oncology journal rankings 2004
109 ranked journals · Subfield in Medicine
Oncology has 109 ranked journals in 2004. The median journal has an OJR of 0.80, below the world average of 1.00, up 0.01 on 2003; Q1 starts at OJR 1.27. The top three are CA A Cancer Journal for Clinicians, Nature Medicine, and Cancer Cell.
Ranks and citation indicators: 2004. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2001–2003, the window the 2004 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery391
- Pulmonary and Respiratory Medicine152
- Public Health, Environmental and Occupational Health137
- Cardiology and Cardiovascular Medicine136
- Oncology109
- Epidemiology94
- Infectious Diseases86
- Psychiatry and Mental health82
- Radiology, Nuclear Medicine and Imaging71
- Neurology68
- Physiology67
- Endocrinology, Diabetes and Metabolism65
Show all 42 subfields
- Orthopedics and Sports Medicine51
- Dermatology49
- Hematology49
- Pediatrics, Perinatology and Child Health49
- Ophthalmology43
- Obstetrics and Gynecology38
- Pharmacology30
- Rheumatology30
- Nephrology28
- Reproductive Medicine25
- Emergency Medicine23
- Complementary and alternative medicine21
- Otorhinolaryngology18
- Pathology and Forensic Medicine16
- Rehabilitation16
- Geriatrics and Gerontology14
- Critical Care and Intensive Care Medicine13
- Immunology and Allergy13
- Genetics8
- Hepatology7
- Anesthesiology and Pain Medicine6
- Gastroenterology6
- Urology5
- Internal Medicine3
- Transplantation2
- Biochemistry1
- Family Practice1
- Anatomy0
- Health Informatics0
- Microbiology0
109 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2003. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2001–2003, the window the 2004 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2001–2003 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2000 to 2004. | Compare |
|---|---|---|---|---|---|---|---|
1CA A Cancer Journal for CliniciansOAWiley · United States | 15.99Q1 | 43.02 13.49 up from 2003 | 66 | 100% | $4,330 | ||
2Nature MedicineNature Portfolio · United States | 6.03Q1 | 14.46 0.87 up from 2003 | 1,169 | 16% | $12,690 | ||
3Cancer CellCell Press · Netherlands | 5.73Q1 | 16.17 1.48 up from 2003 | 270 | 98% | $10,400 | ||
4Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 4.16Q1 | 9.38 0.58 down from 2003 | 2,295 | 5% | — | ||
5JNCI Journal of the National Cancer InstituteOxford University Press · United States | 4.06Q1 | 10.19 0.82 up from 2003 | 762 | 38% | $5,436 | ||
6The Lancet OncologyElsevier BV · United Kingdom | 2.89Q1 | 6.55 0.81 up from 2003 | 333 | 1% | $7,280 | ||
7Clinical Pharmacology & TherapeuticsWiley · United States | 2.88Q1 | 4.45 0.10 down from 2003 | 337 | 2% | $4,410 | ||
8Seminars in Cancer BiologyElsevier BV · United States | 2.62Q1 | 7.75 2.39 up from 2003 | 163 | 4% | $6,060 | ||
9JNCI MonographsOxford University Press · United Kingdom | 2.21Q1 | 7.50 2.19 up from 2003 | 53 | 69% | — | ||
10Seminars in OncologyElsevier BV · United States | 2.09Q1 | 4.99 0.27 down from 2003 | 708 | 1% | $3,550 | ||
11CancerWiley · United States | 2.01Q1 | 4.61 0.49 up from 2003 | 2,529 | 61% | $4,790 | ||
12Current Opinion in OncologyLippincott Williams & Wilkins · United Kingdom | 1.81Q1 | 4.04 0.76 down from 2003 | 209 | 0% | — | ||
13Cancer Causes & ControlSpringer Science+Business Media · Netherlands | 1.70Q1 | 3.40 0.31 up from 2003 | 340 | 7% | $3,890 | ||
14European Journal of CancerElsevier BV · United Kingdom | 1.61Q1 | 3.72 0.21 up from 2003 | 1,183 | 6% | $4,270 | ||
15Cancer Treatment ReviewsElsevier BV · United Kingdom | 1.60Q1 | 3.80 0.21 up from 2003 | 158 | 1% | $4,910 | ||
16International Journal of CancerWiley · United States | 1.60Q1 | 4.26 0.37 up from 2003 | 2,391 | 63% | $5,030 | ||
17The OncologistOAAlphaMed Press · United Kingdom | 1.59Q1 | 4.01 0.50 up from 2003 | 302 | 62% | $3,852 | ||
18JBIC Journal of Biological Inorganic ChemistrySpringer Science+Business Media · Germany | 1.56Q1 | 2.88 0.30 down from 2003 | 296 | 15% | $3,990 | ||
19British Journal of CancerSpringer Nature · United Kingdom | 1.54Q1 | 3.95 0.43 up from 2003 | 2,091 | 98% | $5,190 | ||
20Annals of OncologyElsevier BV · Netherlands | 1.53Q1 | 3.72 0.31 up from 2003 | 1,108 | 97% | $5,080 | ||
21Psycho-OncologyWiley · United Kingdom | 1.51Q1 | 2.45 0.23 down from 2003 | 219 | 11% | $4,940 | ||
22Journal of Mammary Gland Biology and NeoplasiaSpringer Science+Business Media · United States | 1.50Q1 | 3.75 0.14 down from 2003 | 112 | 12% | $4,090 | ||
23Expert Opinion on Investigational DrugsTaylor & Francis · United Kingdom | 1.49Q1 | 3.73 0.24 up from 2003 | 442 | 3% | — | ||
24Cancer ControlOASAGE Publishing · United States | 1.48Q1 | 3.55 0.60 up from 2003 | 149 | 38% | $2,650 | ||
25Critical Reviews in Oncology/HematologyElsevier BV · Netherlands | 1.43Q1 | 3.17 0.06 down from 2003 | 318 | 3% | $4,190 | ||
26Diseases of the Colon & RectumLippincott Williams & Wilkins · United States | 1.42Q1 | 3.28 0.44 up from 2003 | 806 | 3% | — | ||
27Surgical OncologyElsevier BV · United Kingdom | 1.40Q1 | 2.62 0.62 up from 2003 | 70 | 0% | $3,890 | ||
28Cancer NursingLippincott Williams & Wilkins · United States | 1.27Q1 | 2.07 0.22 up from 2003 | 179 | 3% | — | ||
29Journal of ImmunotherapyLippincott Williams & Wilkins · United States | 1.27Q2 | 4.01 0.31 up from 2003 | 192 | 3% | — | ||
30The Cancer JournalLippincott Williams & Wilkins · United States | 1.26Q2 | 2.60 0.15 up from 2003 | 133 | 0% | — | ||
31Clinical & Experimental MetastasisSpringer Science+Business Media · Netherlands | 1.24Q2 | 3.48 0.96 up from 2003 | 171 | 2% | $5,090 | ||
32OncologyKarger Publishers · Switzerland | 1.15Q2 | 2.62 0.08 down from 2003 | 383 | 7% | — | ||
33Cancer Immunology ImmunotherapyOASpringer Science+Business Media · Germany | 1.08Q2 | 3.73 0.21 up from 2003 | 237 | 99% | $4,590 | ||
34Supportive Care in CancerSpringer Science+Business Media · Germany | 1.06Q2 | 1.79 0.06 down from 2003 | 300 | 3% | $4,690 | ||
35BMC CancerOABioMed Central · United Kingdom | 1.05Q2 | 2.99 1.35 up from 2003 | 89 | 100% | $3,390 | ||
36European Journal of Cancer PreventionLippincott Williams & Wilkins · United States | 1.01Q2 | 1.89 0.13 up from 2003 | 244 | 3% | — | ||
37Investigational New DrugsSpringer Science+Business Media · Netherlands | 0.99Q2 | 2.09 0.11 down from 2003 | 150 | 4% | $4,690 | ||
38MicrocirculationWiley · United States | 0.99Q2 | 3.35 1.66 up from 2003 | 228 | 2% | $3,920 | ||
39Cancer InvestigationTaylor & Francis · United Kingdom | 0.96Q2 | 2.29 0.10 up from 2003 | 330 | 6% | — | ||
40Journal of Cancer Research and Clinical OncologyOASpringer Science+Business Media · Germany | 0.96Q2 | 2.65 0.61 up from 2003 | 239 | 100% | $4,390 | ||
41Journal of Clinical PathologyBMJ · United Kingdom | 0.95Q2 | 2.03 0.11 down from 2003 | 814 | 100% | — | ||
42American Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 0.94Q2 | 1.88 0.30 up from 2003 | 451 | 3% | — | ||
43Cancer Chemotherapy and PharmacologySpringer Science+Business Media · Germany | 0.94Q2 | 2.32 0.46 up from 2003 | 299 | 2% | $4,390 | ||
44Acta OncologicaOATaylor & Francis · United Kingdom | 0.92Q2 | 2.01 0.09 down from 2003 | 320 | 100% | — | ||
45Breast Cancer ResearchOABioMed Central · United Kingdom | 0.90Q2 | 2.30 0.78 up from 2003 | 375 | 100% | $4,190 | ||
46Current Treatment Options in OncologySpringer Science+Business Media · United States | 0.90Q2 | 1.73 0.04 up from 2003 | 152 | 4% | $4,890 | ||
47Journal of Medical ScreeningSAGE Publishing · United Kingdom | 0.89Q2 | 2.11no change | 101 | 29% | $4,150 | ||
48Hematology/Oncology Clinics of North AmericaElsevier BV · United States | 0.89Q2 | 1.89 0.32 up from 2003 | 214 | 0% | $3,950 | ||
49Journal of Inorganic BiochemistryElsevier BV · United States | 0.89Q2 | 2.11 0.20 down from 2003 | 621 | 7% | $4,220 | ||
50Journal of Clinical Pharmacy and TherapeuticsWiley · United Kingdom | 0.87Q2 | 1.29 0.06 down from 2003 | 197 | 59% | $2,700 |
Subfields of Medicine, with Oncology highlighted.
- Surgery391
- Pulmonary and Respiratory Medicine152
- Public Health, Environmental and Occupational Health137
- Cardiology and Cardiovascular Medicine136
- Oncology109
- Epidemiology94
- Infectious Diseases86
- Psychiatry and Mental health82
- Radiology, Nuclear Medicine and Imaging71
- Neurology68
- Physiology67
- Endocrinology, Diabetes and Metabolism65
- Orthopedics and Sports Medicine51
- Dermatology49
- Hematology49
- Pediatrics, Perinatology and Child Health49
- Ophthalmology43
- Obstetrics and Gynecology38
- Pharmacology30
- Rheumatology30
- Nephrology28
- Reproductive Medicine25
- Emergency Medicine23
- Complementary and alternative medicine21
- Otorhinolaryngology18
- Pathology and Forensic Medicine16
- Rehabilitation16
- Geriatrics and Gerontology14
- Critical Care and Intensive Care Medicine13
- Immunology and Allergy13
- Genetics8
- Hepatology7
- Anesthesiology and Pain Medicine6
- Gastroenterology6
- Urology5
- Internal Medicine3
- Transplantation2
- Biochemistry1
- Family Practice1
- Anatomy0
- Health Informatics0
- Microbiology0
Journals
Citations made in 2004. Corpus-wide, 69.4% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
25 additional Oncology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2001–2003, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2004. Publication window: 2001–2003. How these summaries are calculated
- Ranked journals
- 109
- Window papers (baseline)
- 49,058 +18.4% from indicator year 2001
- Median OJR
- 0.805 +30.0% from indicator year 2001
- Rising journals (2025)
- 20
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2001–2003 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 82 | 88 | 96 | 103 | 109 | 120 | 120 | 126 | 127 | 134 | 141 | 150 | 153 | 170 | 179 | 188 | 198 | 213 | 224 | 234 | 238 | 239 | 245 | 245 | 243 | 242 | |
| Window papers (baseline) | 37,821 | 41,430 | 44,340 | 47,392 | 49,058 | 53,111 | 57,002 | 62,106 | 66,087 | 71,283 | 77,009 | 82,075 | 86,189 | 88,804 | 93,912 | 98,660 | 102,921 | 105,891 | 109,984 | 115,044 | 121,890 | 139,666 | 156,942 | 167,602 | 163,907 | 160,807 | |
| Median OJR | 0.55 | 0.62 | 0.70 | 0.799 | 0.805 | 0.831 | 0.85 | 0.90 | 0.94 | 0.93 | 1.010 | 0.95 | 1.006 | 0.974 | 0.972 | 0.967 | 0.832 | 0.84 | 0.82 | 0.79 | 0.829 | 0.830 | 0.77 | 0.750 | 0.73 | 0.748 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.